cdp.cancer.gov Open in urlscan Pro
2607:f220:41d:21c1::812b:fe66  Public Scan

Submitted URL: http://www.cancerdiagnosis.nci.nih.gov/
Effective URL: https://cdp.cancer.gov/
Submission: On December 04 via api from US — Scanned from AU

Form analysis 1 forms found in the DOM

Name: SearchFormGET /search/search.asp

<form action="/search/search.asp" method="get" enctype="application/x-www-form-urlencoded" name="SearchForm" id="SearchForm" onsubmit="return validate_search();">
  <label id="searchLabel" for="zoom_query">Search this site</label>
  <input type="text" name="zoom_query" id="zoom_query" maxlength="255" class="search" value="Search this site">
  <input class="searchButton" id="mobileSearchButton" type="image" src="/images/redesign/mb_search.png" name="Action" alt="Search">
</form>

Text Content

Skip to Content
Home | Sitemap | Contact CDP
Search this site

 * Home
 * About CDP
   * Mission Statement and Branches
   * Staff Directory
   * Office of the Associate Director (OAD)
   * Biorepositories and Biospecimen Research Branch (BBRB)
   * Diagnostic Biomarkers and Technology Branch (DBTB)
   * Diagnostics Evaluation Branch (DEB)
   * Pathology Investigation and Resources Branch (PIRB)
 * Scientific Programs
   * Precision Medicine Trials
   * MoCha Lab
   * Exceptional Responders
   * CIMAC-CIDC
   * Strategic Partnering to Evaluate Cancer Signatures (SPECS)
     * Overview
     * SPECS Projects
   * TAILORx
 * Funding Opportunities
   * Current Funding Opportunities
   * Complete List of Cancer Diagnosis Program Initiatives
   * P01 Program Development Guidance
   * Additional Funding Opportunities and Useful Tools
 * Resources
   * Templates for Clinical Assay Development
   * Assay Harmonization Resources
   * Technology Development Resources
   * Diagnostics Research and Development Resources
   * Human Specimen Resources
   * Ethical, Legal and Social Implications of Biobanking in Cancer Research
 * News and Publications
   * News
   * Publications
 * Recommendations

 * Funding Opportunities
 * GTEx Biobank
 * NCTN Navigator
 * Clinical Trial Applications


WELCOME TO THE CANCER DIAGNOSIS PROGRAM!

The Cancer Diagnosis Program strives to improve the diagnosis and assessment of
cancer by effectively moving new scientific knowledge into clinical practice.
This national program stimulates, coordinates and funds resources and research
for the development of innovative in vitro diagnostics, novel diagnostic
technologies and appropriate human specimens in order to better characterize
cancers and allow improved medical decision making and evaluation of response to
treatment.

For more information about the Cancer Diagnosis Program and its Branches, please
click here.


NEWS AND ANNOUNCEMENTS

10/2024
Registration is now open for the Transformative Microsystem Technologies for
Cancer Diagnostics, Monitoring Treatment Response, and Management Workshop,
taking place virtually on February 5-6, 2025. View the agenda and register for
the workshop on the event website here.
02/2024
Summary and recordings from the March 2024 NCI Workshop on Digital Pathology
Imaging (DPI) in Cancer Clinical Trials and Research are now available here.
07/2023
Summary and recordings from the September 2023 NCI Workshop on ctDNA in Cancer
Treatment and Clinical Care are now available here.
01/2023
Guidance for investigators interested in P01 Funding for DCTD research areas is
now available here.
06/2022
Visit this page to see the schedule of CDP and other DCTD programs presentations
at 2022 ASCO.
04/2022
Click here to see a list of presentations by CDP and other DCTD programs at 2022
AACR.
03/2022
CDP’s Dr. Magdalena Thurin participated in ASCO/CAP Immune Checkpoint Inhibitor
(ICI) Predictive Factor Virtual Summit in September 2021; slides and recordings
are now available here. 
11/2021
In September, NCI hosted the FDA/NIH Next Generation Sequencing and Radiomics
Workshop: Resource Requirements for Acceleration of Clinical Applications
Including Artificial Intelligence.
10/2021
CDP's Dr. Brian Sorg is involved in a cross-agency collaboration with NASA, FDA,
NIH, and HHS's BARDA that could lead to unprecedented advancements personalized
medicine by extending the life of tissue chips.
09/2021
Dr. Lyndsay Harris, Associate Director of the CDP, commemorates the 50th
anniversary of the National Cancer Act with a Staff Highlight in the DCTD
newsletter on the evolution of cancer biomarkers, diagnostics, and where
research is headed.


QUICK LINKS

P01 Program Development Guidance
NCI COVID-19 Research Initiatives
The NCI Grants Process
Templates for Clinical Assay Development
Biorepositories and Biospecimen Research Branch
“Omics” Checklist — Criteria For Use of Omics-based Predictors in Clinical
Trials
Ethical, Legal and Social Implications of Biobanking in Cancer Research
NCI-MATCH/EAY131
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)


STAY CONNECTED

Sign up for Email Updates
Follow us on Twitter
Contact Us
 * CDP Home
 * Contact CDP
 * Site Map
 * Accessibility
 * Disclaimer
 * FOIA
 * Privacy & Security
 * HHS Vulnerability Disclosure

 * U.S. Department of Health and Human Services
 * National Institutes of Health
 * National Cancer Institute
 * USA.gov

NIH… Turning Discovery Into Health®